- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in PROTACs for Drug Targeted Protein Research
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 18, Pages 10328
Publisher
MDPI AG
Online
2022-09-08
DOI
10.3390/ijms231810328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer
- (2021) Hidetomo Yokoo et al. ACS Medicinal Chemistry Letters
- Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL
- (2021) Lorena Fontan et al. BLOOD
- Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
- (2021) Zhangping Xiao et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A patent review of MALT1 inhibitors (2013-present)
- (2021) Isabel Hamp et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
- (2021) Mengzhu Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
- (2021) Troy A. Bemis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6
- (2021) Zhuoxian Cao et al. ACS Chemical Biology
- Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
- (2021) Jaeki Min et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
- (2021) Satomi Imaide et al. Nature Chemical Biology
- IRAK family in inflammatory autoimmune diseases
- (2020) Lin-Chong Su et al. AUTOIMMUNITY REVIEWS
- DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia
- (2020) Yonghan He et al. BLOOD
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2, 3-dioxygenase 1
- (2020) Mingxing Hu et al. Acta Pharmaceutica Sinica B
- Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
- (2020) Arun K. Ghosh et al. ChemMedChem
- Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects
- (2020) Cara H. Nelson et al. CLINICAL PHARMACOKINETICS
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase
- (2020) Mei-Xin Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?
- (2020) Eugenio Cavalli et al. MOLECULES
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- PROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer’s and Parkinson’s Diseases
- (2020) Robert B. Kargbo ACS Medicinal Chemistry Letters
- HaloTag‐targeted Sirtuin rearranging ligand (SirReal) for the development of proteolysis targeting chimeras (PROTACs) against the lysine deacetylase Sirtuin 2 (Sirt2)
- (2020) Matthias Schiedel et al. CHEMBIOCHEM
- PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases
- (2020) Xueyang Jiang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The therapeutic potential of PROTACs
- (2020) Andrew B. Benowitz et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
- (2020) Liqun Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
- (2020) Sébastien L. Degorce et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation
- (2020) Venkat Giri Magupalli et al. SCIENCE
- Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer
- (2020) Manish Charan et al. Cell Death & Disease
- Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
- (2020) Fangyuan Cao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs
- (2020) Yun Chen et al. ACS Medicinal Chemistry Letters
- Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo
- (2020) Guoshun Luo et al. Acta Pharmaceutica Sinica B
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Treatment of Alzheimer’s by PROTAC-Tau Protein Degradation
- (2019) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
- (2019) Michael L. Drummond et al. Journal of Chemical Information and Modeling
- Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
- (2019) William T. McElroy EXPERT OPINION ON THERAPEUTIC PATENTS
- SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
- (2019) Michael J. Roy et al. ACS Chemical Biology
- Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
- (2019) M Catarina Silva et al. eLife
- Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
- (2019) Laura Soumoy et al. Cancers
- Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
- (2019) Meiyang Xi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
- (2019) Jessica N. Spradlin et al. Nature Chemical Biology
- Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
- (2019) Mélissanne de Wispelaere et al. Nature Communications
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
- (2019) Jiuling Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Neutrophils deficient in innate suppressor IRAK-M enhances anti-tumor immune responses
- (2019) Yao Zhang et al. MOLECULAR THERAPY
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
- (2019) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort
- (2019) Malathi Kandarpa et al. BLOOD
- Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas
- (2019) Lorena Fontan et al. BLOOD
- Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models
- (2019) Qi Zhang et al. BLOOD
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
- (2018) Shanshan Gu et al. BIOESSAYS
- Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative
- (2018) Shusuke Tomoshige et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- When Kinases Meet PROTACs
- (2018) Li Tan et al. CHINESE JOURNAL OF CHEMISTRY
- Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
- (2018) Mengchen Lu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
- (2018) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An oral androgen receptor PROTAC degrader for prostate cancer.
- (2018) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses
- (2018) Kristen N. Balogh et al. PLoS One
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
- (2018) Zuni I. Bassi et al. ACS Chemical Biology
- Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
- (2018) Kristin M. Riching et al. ACS Chemical Biology
- Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
- (2018) Chung Hyo Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
- (2018) Raphael Koch et al. BLOOD
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
- (2018) Tatsuya Nagano et al. CURRENT CANCER DRUG TARGETS
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders
- (2017) Scott J. Hughes et al. Essays in Biochemistry
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe
- (2017) Philip G. Humphreys et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- NASH: Novel therapeutic strategies targeting ASK1 in NASH
- (2017) Susanne Schuster et al. Nature Reviews Gastroenterology & Hepatology
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes
- (2016) Zeynep Yurtsever et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- IRAK-M Expression in Tumor Cells Supports Colorectal Cancer Progression through Reduction of Antimicrobial Defense and Stabilization of STAT3
- (2016) Rebecca Kesselring et al. CANCER CELL
- TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
- (2016) Anna C. Groner et al. CANCER CELL
- BET inhibitors in cancer therapeutics: a patent review
- (2016) Anirban Ghoshal et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Pancreatic cancer: yesterday, today and tomorrow
- (2016) Daniel Ansari et al. Future Oncology
- Epigenetics of hematopoiesis and hematological malignancies
- (2016) Deqing Hu et al. GENES & DEVELOPMENT
- Diagnostic and Therapeutic Strategies for Prostate Cancer
- (2016) Mary Nguyen-Nielsen et al. SEMINARS IN NUCLEAR MEDICINE
- GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington’s disease: involvement of astrocyte–neuron interactions
- (2016) F L'Episcopo et al. Cell Death & Disease
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Modulating mammary tumor growth, metastasis and immunosuppression by siRNA-induced MIF reduction in tumor microenvironment
- (2015) M Zhang et al. CANCER GENE THERAPY
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Selective Inhibition of SIRT2 Improves Outcomes in a Lethal Septic Model
- (2015) T. Zhao et al. CURRENT MOLECULAR MEDICINE
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors
- (2015) Ha-Soon Choi et al. ACS Medicinal Chemistry Letters
- The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation
- (2015) Zeynep Yurtsever et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma
- (2014) Camila S Oliveira et al. BMC CANCER
- IRAK signalling in cancer
- (2014) G W Rhyasen et al. BRITISH JOURNAL OF CANCER
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- RIP kinases: key decision makers in cell death and innate immunity
- (2014) F Humphries et al. CELL DEATH AND DIFFERENTIATION
- Understanding the Roles of FAK in Cancer
- (2014) Hyunho Yoon et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Cooperative Regulation of Non-Small Cell Lung Carcinoma Angiogenic Potential by Macrophage Migration Inhibitory Factor and Its Homolog, D-Dopachrome Tautomerase
- (2014) A. M. Coleman et al. JOURNAL OF IMMUNOLOGY
- Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders
- (2014) Divya Chaudhary et al. JOURNAL OF MEDICINAL CHEMISTRY
- Privileged Structures: Efficient Chemical “Navigators” toward Unexplored Biologically Relevant Chemical Spaces
- (2014) Jonghoon Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
- (2014) Asli Muvaffak et al. MOLECULAR CANCER RESEARCH
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Knockdown of Tripartite Motif Containing 24 by Lentivirus Suppresses Cell Growth and Induces Apoptosis in Human Colorectal Cancer Cells
- (2014) Jianwei Wang et al. ONCOLOGY RESEARCH
- Overexpression of TRIM24 Is Associated with the Onset and Progress of Human Hepatocellular Carcinoma
- (2014) Xiao Liu et al. PLoS One
- Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
- (2014) T. N. Chonghaile et al. Cancer Discovery
- Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
- (2014) Christine Victoria Ichim Stem Cells Translational Medicine
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells
- (2013) Keiichiro Okuhira et al. CANCER SCIENCE
- SIRT1 and SIRT2: emerging targets in neurodegeneration
- (2013) Gizem Donmez et al. EMBO Molecular Medicine
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
- (2013) Michael R. Grunwald et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS
- (2013) M. H. Yang et al. MOLECULAR CANCER RESEARCH
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- TRIM24 Overexpression Is Common in Locally Advanced Head and Neck Squamous Cell Carcinoma and Correlates with Aggressive Malignant Phenotypes
- (2013) Zhibin Cui et al. PLoS One
- A Role for SIRT2-Dependent Histone H3K18 Deacetylation in Bacterial Infection
- (2013) H. A. Eskandarian et al. SCIENCE
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
- (2012) B. Will et al. BLOOD
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- IL-13–induced airway mucus production is attenuated by MAPK13 inhibition
- (2012) Yael G. Alevy et al. JOURNAL OF CLINICAL INVESTIGATION
- The Central Theme of Parkinson’s Disease: α-Synuclein
- (2012) Mehmet Ozansoy et al. MOLECULAR NEUROBIOLOGY
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
- (2012) Oliver Hantschel et al. Nature Chemical Biology
- Overexpression of TRIM24 Correlates with Tumor Progression in Non-Small Cell Lung Cancer
- (2012) Haiying Li et al. PLoS One
- Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors
- (2011) Hongbo Zeng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity
- (2011) Hyun-Seok Kim et al. CANCER CELL
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
- (2011) M. Cargnello et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Mechanisms and functions of p38 MAPK signalling
- (2010) Ana Cuadrado et al. BIOCHEMICAL JOURNAL
- PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments
- (2010) Isabelle Tanjoni et al. CANCER BIOLOGY & THERAPY
- Colon cancer
- (2010) Roberto Labianca et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus
- (2010) MaSalomé Sirerol-Piquer et al. HIPPOCAMPUS
- Chemical Inducers of Targeted Protein Degradation
- (2010) Kanak Raina et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TRIM24 links a non-canonical histone signature to breast cancer
- (2010) Wen-Wei Tsai et al. NATURE
- Protacs for Treatment of Cancer
- (2010) Kathleen M Sakamoto PEDIATRIC RESEARCH
- Inhibition of p38: Has the fat lady sung?
- (2009) Mark C. Genovese ARTHRITIS AND RHEUMATISM
- Nonproteolytic Functions of Ubiquitin in Cell Signaling
- (2009) Zhijian J. Chen et al. MOLECULAR CELL
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
- (2008) K. W. Pratz et al. BLOOD
- Roles of unphosphorylated STATs in signaling
- (2008) Jinbo Yang et al. CELL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search